Dr ravi savarirayan biography for kids

Home / Related Biographies / Dr ravi savarirayan biography for kids

[3]

No difference in efficacy or safety could be identified between the once-daily doses of 15 and 30 μg per kilogram; thus, the findings support the choice of the lower dose (15 μg) for further evaluation in ongoing studies. After I went back to Australia and finished my doctorate, I began to see firsthand what life was like for children with these conditions.

dr ravi savarirayan biography for kids

Ravi Savarirayan and his team published a paper in the New England Journal of Medicine with results from Biomarin's Vosoritide phase 2 dose-finding and extension study for children with achondroplasia aged 5-14 years, showing a sustained increase in annualized growth velocity.

 

This study enrolled a total of 35 children who were divided into 4 cohortsreceiving different doses of the drug (2.5, 7.5, 15 and 30 μg per kilogram of body weight).

C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. Annualized growth velocity was observed to increase by up to 2.34 cm/year compared to the baseline measurements taken in the last 6 months of the observation study they were previously enrolled in. Matthew L Stone pediatrics
University of Virginia Health System; Charlottesville, VA
United States of America

  • Dr.

    Ravi Savarirayan has been at the forefront of research advancing care for children with skeletal conditions, including achondroplasia, for more than two decades. L Stone

    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America

  • Dr.

    A clinical geneticist by training, Dr.

    Savarirayan serves as Group Leader of Skeletal Biology at Murdoch Children’s Research Institute in Melbourne, Australia. After 6 months the 2.5 μg group's dose was increased to 7.5 μg and the 7.5 μg group was increased to 15 μg and the treatment continued for up to 42 months. Adverse events are different from adverse effects/reactions, in the sense that adverse events are any health complications that might be observed in a patient during a clinical trial, not necessarily linked to the treatment being administered, and adverse effects are any noxious or unintended effects that can be attributed directly to the treatment being administered in a clinical trial.

    Pharmacovigilance Glossary. 

    • Driving Progress for Children with Achondroplasia

    Dr. William pediatrics
    Maimonides Medical Center
    United States of America

    Dr. I eventually became the lead investigator on BioMarin’s study evaluating a potential new medicine.

    R Ismail, pediatrics
    King Abdul Aziz University
    United Arab Emirates

  • Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates

  • Dr. During his visit, he spoke to employees about why he has dedicated his career to improving the lives of people with skeletal dysplasias, progress over the past two decades and where he hopes to see the field go next.

    • .

    Although in cohorts 3 and 4, who were continuously given 15 and 30μg of vosoritide per kg of body weight respectively, the highest increase in annualized growth velocity was observed, there wasn't a significant difference between these two doses. Read below to learn more about what Dr. Savarirayan shared with us.

    Q: Can you tell us a little bit about your career journey and what inspired you to push for advancements in skeletal dysplasia care?

    I came to the United States in 1998 as a Fulbright Scholar and worked at UCLA with Dr.

    David Rimoin, a pioneer in genetics who I was lucky enough to have as my mentor. R Sameh pediatrics
    King Abdul Aziz University
    United Arab Emirates

  • Dr. I went home and said to my wife “I think I need to see whether we can work out how to better manage and treat this condition.”

    Around the same time, I began working with BioMarin.